Alaunos Therapeutics logo

Alaunos TherapeuticsNASDAQ: TCRT

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

24 August 2005

Next earnings report:

14 August 2024

Last dividends:

N/A

Next dividends:

N/A
$10.41 M
-98%vs. 3y high
18%vs. sector
-vs. 3y high
-vs. sector
-89%vs. 3y high
59%vs. sector
1.73 K
-80%vs. 3y high
99%vs. sector

Price

after hours | Mon, 01 Jul 2024 20:04:20 GMT
$0.65-$0.05(-7.00%)

Dividend

No data over the past 3 years
$1.00 K-$1.68 M

Analysts recommendations

Institutional Ownership

TCRT Latest News

Alaunos (TCRT) to Wind Down Sole Clinical Study, Stock Dips 65%
Zacks Investment Research16 August 2023 Sentiment: NEGATIVE

Due to a lack of funding needs, Alaunos (TCRT) decides to end its only clinical study. The company will instead focus on its hunTR TCR discovery platform and explore broad strategic alternatives.

Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April
GlobeNewsWire29 March 2023 Sentiment: POSITIVE

HOUSTON, March 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that company management will be participating in the following upcoming investor conferences.

What type of business is Alaunos Therapeutics?

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.

What sector is Alaunos Therapeutics in?

Alaunos Therapeutics is in the Healthcare sector

What industry is Alaunos Therapeutics in?

Alaunos Therapeutics is in the Biotechnology industry

What country is Alaunos Therapeutics from?

Alaunos Therapeutics is headquartered in United States

When did Alaunos Therapeutics go public?

Alaunos Therapeutics initial public offering (IPO) was on 24 August 2005

What is Alaunos Therapeutics website?

https://www.alaunos.com

Is Alaunos Therapeutics in the S&P 500?

No, Alaunos Therapeutics is not included in the S&P 500 index

Is Alaunos Therapeutics in the NASDAQ 100?

No, Alaunos Therapeutics is not included in the NASDAQ 100 index

Is Alaunos Therapeutics in the Dow Jones?

No, Alaunos Therapeutics is not included in the Dow Jones index

When does Alaunos Therapeutics report earnings?

The next expected earnings date for Alaunos Therapeutics is 14 August 2024